The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02782429

Acronym

KeCoDy

Enrollment

Registered

2016-05-25

Start date

2016-04-30

Completion date

Unknown

Last updated

2016-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amnestic, Cognitive Disorders, Delirium, Dementia, Inflammation

Keywords

ketamine, Cardiac Surgery, Neurocognitive Disorders

Brief summary

The purpose of this study is to analyze the Ketamine with its anti-inflammatory profile would be able to prevent cognitive disorders in the postoperative period of cardiac surgery, since these disorders contribute to an impact on morbidity / mortality in this population.

Interventions

DRUGKetamine

OTHERSaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged over 50 years. * Be submitted to cardiac surgery by sternotomy and with the use of cardiopulmonary bypass (CPB). * American Society of Anesthesiologists classification 1, 2,3 and 4.

Exclusion criteria

* Patients undergoing reoperation. * Patients undergoing heart transplantation. * Patients using vasopressor agents and / or ionotropic continuous preoperatively. * Patients with prior endotracheal intubation and consequently Ventilatory Assistance Mechanics. * Patients with documented psychiatric disorders. * Patients with previous cognitive disorders. * Patients with a history of alcohol or drug abuse. * Patients with a history of cerebrovascular accident (CVA) with less than 3 months.

Design outcomes

Primary

Measure	Time frame
Change in cognitive disorder, defined by a drop of 2 points in the Mini-Mental State Examination	Baseline and 7 days
Detectable levels of inflammatory biomarkers in bloodstream, such as: P-selectin (CD62p- ng/ml), CD40L soluble (ng/ml), s100B (ng/ml)	Change from baseline at 6 hours and 24 hours after surgery

Secondary

Measure	Time frame
Delirium assessed using the Confusion Assessment Method (CAM)	24 hours after surgery
Sternotomy Pain assessed using the Visual Analogue Scale	24 hours after surgery

Countries

Brazil

Contacts

Primary ContactRebeca GA Andrade, master

bekinhagonelli@hotmail.com+55 81 988043844

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026